Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2012  |  Volume : 8  |  Issue : 3  |  Page : 464

A vanishing act: The incredible erlotinib

Department of Hematology and Oncology, Wyckoff Heights Medical Center, Brooklyn, NY 11209, USA

Date of Web Publication17-Nov-2012

Correspondence Address:
Shitij Arora
Room 405, Wyckoff Heights Medical Center, 374, Stockholm Street, NY 11237
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-1482.103539

Rights and Permissions

How to cite this article:
Arora S, Sawhney H. A vanishing act: The incredible erlotinib. J Can Res Ther 2012;8:464

How to cite this URL:
Arora S, Sawhney H. A vanishing act: The incredible erlotinib. J Can Res Ther [serial online] 2012 [cited 2022 Jul 5];8:464. Available from: https://www.cancerjournal.net/text.asp?2012/8/3/464/103539


A 57-year-old male with 100-pack-year smoking history came to our hospital with shortness of breath. Imaging revealed multiple bilateral nodules (Panel a) which on biopsy showed a focally mucin producing, broncho-alveoloar carcinoma [Figure 1]. He was started on cisplatinum and gemcitabine. After 2 cycles, there was no evident reduction in the bulk of the disease. Mutational analysis studies suggested EGFR mutation (deletion of exon 19) and the patient was then started on erlotinib monotherapy. The follow up chest X-ray done at 3 months post erlotinib therapy is shown in Panel b [Figure 1].
Figure 1: Image on the left (Panel a) shows the chest x ray in June 2011. On the right (Panel b) is shown the chest x ray in September 2011 after 4 months of monotherapy with Erlotinib. Patient showed a dramatic clinical response with siginifi cant improvement in MMRC dyspnea scale

Click here to view

Tyrosine Kinase Inhibitors (Erlotinib, Nilotinib) are a recommended therapy for advanced non small cell lung cancer (NSCLC) with epidermal growth factor receptor mutations. In a study comparing erlotinib alone versus erlotinib/carboplatin/paclitaxel in patients with advanced NSCLC (CALGB 30406), [1] erlotinib was associated with fewer adverse effects.

 > References Top

1.Jänne PA, Wang XF, Socinski MA, Crawford J, Capelletti M, Edelman MJ, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol. 2012 Jun 10;30(17):2063-9.  Back to cited text no. 1


  [Figure 1]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Article Figures
  In this article

 Article Access Statistics
    PDF Downloaded135    
    Comments [Add]    

Recommend this journal